NeoGenomics, Inc. (NEO) vs Intellia Therapeutics, Inc. (NTLA)

A side-by-side comparison of NeoGenomics, Inc. and Intellia Therapeutics, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 2, 2026. Differences are shown without an overall score or investment verdict.

Compare

Total return — NEO vs NTLA

growth of $100 · dividends reinvested · last 10y
NEO +117.9% (+8.1%/yr)NTLA -30.1% (-3.5%/yr)NEO compounded faster over this window
02004006008001kStart $10020182020202220242026$218$70
NEO NTLA

NEO vs NTLA: by the numbers

  • •NTLA is the larger company ($1.71B vs $475M market cap).
  • •Both run net losses; NEO's is the smaller (-6.77% vs -672.16% net margin).
  • •NEO grew revenue faster over the past five years (9.41% vs 7.31% CAGR).

Metrics side by side

Valuation

MetricNEONTLA
Forward P/E101.08N/A
P/S ratio0.6228.79
P/B ratio0.602.35

Profitability

MetricNEONTLA
Gross margin42.92%76.47%
Operating margin-8.63%-651.67%
Net margin-6.77%-672.16%
ROE-6.60%-54.96%
ROIC-5.29%-54.45%

Growth (annualized)

MetricNEONTLA
Revenue CAGR (5Y)9.41%7.31%
Total return CAGR (5Y)-18.18%-38.17%

Frequently asked

Which has grown faster, NEO or NTLA?
Over the past five years, NEO grew revenue faster — NEO at a 9.41% CAGR versus NTLA at 7.31%.
How have NEO and NTLA total returns compared?
Over the past 10 years, NEO delivered 8.10% and NTLA delivered -3.34% annualized total return. Past performance doesn't predict future results.

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 2, 2026.